History has shown that when manufacturers skimp on sterile filtration of drugs, the consequences can amount to the loss of ...

The Food and Drug Administration approved Myqorzo, a once-daily pill containing the active ingredient aficamten, for adults ...

Onconic Therapeutics said its gastroesophageal reflux disease drug Zacubo (zastaprazan) will be available for broader combination prescriptions after clinical t ...

Raising awareness and educating individuals about the potential risks associated with botanical supplements and their ...

Multimorbidity — the co-occurrence of two or more chronic conditions in a single patient — is now the norm rather than the exception in most healthcare ...

A study reveals that non-cardiovascular medications increase hospital readmission risks in heart failure patients, ...

Polypharmacy in patients with cardiovascular disease occurs frequently across the age spectrum and can lead to inappropriate ...

Roughly one in nine Americans aged 65 and older is exposed to a prescription drug combination flagged as a major drug-drug ...

Polypharmacy, the concurrent use of multiple medications by a single patient, has become one of the most significant challenges in modern healthcare. While often necessary for managing multiple ...

Globally, adverse drug events (ADEs) affect over 2 million patients annually in the US alone, causing ~770,000 injuries. Polypharmacy (taking 5+ medications) affects 30-40% of elderly patients. The ...

Learn how zangontinib affects atorvastatin, raises liver-risk, and why frequent LFTs plus entecavir may prevent hepatitis B reactivation. William takes 7 daily medications (metformin, lisinopril, ...

In this segment, Dr. Charles J. Ryan asks Dr. Murilo De Almeida Luz to discuss the importance of evaluating drug drug interaction profiles when selecting androgen receptor pathway inhibitors for ...